{
    "nctId": "NCT06638307",
    "briefTitle": "A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer",
    "officialTitle": "A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 124,
    "primaryOutcomeMeasure": "Number of Participants Experiencing Dose-limiting Toxicity When Administered MEN2312",
    "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Participants with advanced breast cancer that cannot be cured.\n* Participant must have received at least one prior line of endocrine therapy for advanced/metastatic disease. Progression on previous cyclin-dependent kinase 4/6 inhibitor treatment in combination with fulvestrant or aromatase inhibitor is required.\n* Up to 6 prior lines of therapy are allowed. Up to 2 prior chemotherapy and/or cytotoxic antibody-drug conjugates regimens in the advanced/metastatic setting is permitted.\n\nKey Exclusion Criteria:\n\n* New or active brain metastasis.\n* Severe internal organ spread that could cause immediate life-threatening problems, including large uncontrolled fluid build-up or severe lung or liver involvement.\n\nNote: Other inclusion/exclusion criteria may apply.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}